Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FOLD Amicus Therapeutics

Closed 02-02 16:00:00 EST

14.29

+0.00

0.00%

盘后14.29

+0.000.00%

19:56 EST

High14.30	Low14.28	Vol7.78M
Open14.29	D1 Closing14.29	Amplitude0.14%
Mkt Cap4.49B	Tradable Cap4.44B	Total Shares314.00M
T/O111.16M	T/O Rate2.50%	Tradable Shares311.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FOLD","market":"US","secType":"STK","nameCN":"Amicus Therapeutics","latestPrice":14.29,"timestamp":1770066000000,"preClose":14.29,"halted":0,"volume":7777586,"hourTrading":{"tag":"盘后","latestPrice":14.29,"preClose":14.29,"latestTime":"19:56 EST","volume":90469,"amount":1292804.47,"timestamp":1770080168218,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":311000000,"shares":314000000,"eps":-0.045705,"marketStatus":"Closed","change":0,"latestTime":"02-02 16:00:00 EST","open":14.29,"high":14.3,"low":14.28,"amount":111163411.18252599,"amplitude":0.0014,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.045705,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770109200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1180584000000,"exchange":"NASDAQ","adjPreClose":14.29,"preHourTrading":{"tag":"盘前","latestPrice":14.29,"preClose":14.29,"latestTime":"09:27 EST","volume":5979,"amount":85438.152174,"timestamp":1770042460201,"change":0,"changeRate":0,"amplitude":0.003072},"postHourTrading":{"tag":"盘后","latestPrice":14.29,"preClose":14.29,"latestTime":"19:56 EST","volume":90469,"amount":1292804.47,"timestamp":1770080168218,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.232587,"impliedVol":0.508,"impliedVolPercentile":0.5857},"requestUrl":"/m/hq/s/FOLD","defaultTab":"news","newsList":[{"id":"2607068258","title":"Is It Time To Reassess Amicus Therapeutics (FOLD) After Last Year’s 48.9% Gain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2607068258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607068258?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:29","pubTimestamp":1769718554,"startTime":"0","endTime":"0","summary":"If you are wondering whether Amicus Therapeutics at around US$14.28 is offering good value today, the key is to look past the share price and focus on what the underlying valuation signals are telling you.\nThe stock has been relatively flat over the past month with a 0.2% return, but the 48.9% return over the last year contrasts with a small 0.5% decline in the last 7 days and a modest 0.1% return year to date, which can change how investors see both its potential and its risks.\nRecent...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/is-it-time-to-reassess-amicus-therapeutics-fold-after-last-y","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/is-it-time-to-reassess-amicus-therapeutics-fold-after-last-y","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","LU2065171402.SGD","LU2065171311.SGD","LU2065169927.USD","LU2065170008.USD","FOLD","BK4139"],"gpt_icon":0},{"id":"2606620980","title":"Amicus Therapeutics: Solid Fundamentals but Limited Upside Amid BioMarin Takeover, Justifying Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2606620980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606620980?lang=en_us&edition=fundamental","pubTime":"2026-01-27 15:55","pubTimestamp":1769500528,"startTime":"0","endTime":"0","summary":"Ritu Baral, an analyst from TD Cowen, maintained the Hold rating on Amicus. The associated price target remains the same with $14.50. Ritu Baral ha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/amicus-therapeutics-solid-fundamentals-but-limited-upside-amid-biomarin-takeover-justifying-hold-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/amicus-therapeutics-solid-fundamentals-but-limited-upside-amid-biomarin-takeover-justifying-hold-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FOLD"],"gpt_icon":0},{"id":"2605090446","title":"Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605090446","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605090446?lang=en_us&edition=fundamental","pubTime":"2026-01-23 08:27","pubTimestamp":1769128051,"startTime":"0","endTime":"0","summary":"Bradley L. Campbell, President and CEO of Amicus Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nNDL783nyB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","FOLD","LU2065171402.SGD","LU2065170008.USD","BK4139","LU2065169927.USD"],"gpt_icon":0},{"id":"2605491110","title":"Amicus Therapeutics Cut to Hold From Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605491110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605491110?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:25","pubTimestamp":1769088300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FOLD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2026 08:25 ET (13:25 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BK4139","LU2065169927.USD","LU2065171311.SGD","LU2065170008.USD","FOLD"],"gpt_icon":0},{"id":"2605910496","title":"Jefferies Downgrades Amicus Therapeutics to Hold From Buy, Adjusts Price Target to $14.50 From $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2605910496","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605910496?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:39","pubTimestamp":1769085558,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (FOLD) has an average rating of hold and mean price target of $14.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FOLD"],"gpt_icon":0},{"id":"2605676374","title":"Amicus downgraded to Hold from Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605676374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605676374?lang=en_us&edition=fundamental","pubTime":"2026-01-22 18:15","pubTimestamp":1769076932,"startTime":"0","endTime":"0","summary":"Jefferies downgraded Amicus (FOLD) to Hold from Buy with a price target of $14.50, down from $16. Proxy documents show the company did receive exte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amicus-downgraded-to-hold-from-buy-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amicus-downgraded-to-hold-from-buy-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065170008.USD","BK4139","LU2065171311.SGD","FOLD","LU2065171402.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"2605450781","title":"U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605450781","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605450781?lang=en_us&edition=fundamental","pubTime":"2026-01-22 15:17","pubTimestamp":1769066226,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne TechnologiesJan 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cencor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL4N3YN0FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0316494557.USD","BTSG","BKU","CNC","EOLS","GOLF","HAL","KRMN","EGBN","NIC","SCHW","CAH","DCOM","RAPT","LEGN","LU0882574055.USD","BXP","ACHC","CTSH","COR","GLDD","LU0477156953.USD","LU2931357623.SGD","MOH","GDRX","MCB","IE00BKVL7J92.USD","SSNC","BK4122","KTOS","CROX","FOLD","OPCH","OZK","LU0234570918.USD","CHE","MKSI","CVLT","NOW","REAL","LU1119994496.HKD","JNJ","ORN","LU0965509101.SGD","CFG","KMI","MRK","IE000M9KFDE8.USD","HCA"],"gpt_icon":1},{"id":"2605457687","title":"Amicus Therapeutics Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $14.5 From $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2605457687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605457687?lang=en_us&edition=fundamental","pubTime":"2026-01-22 14:39","pubTimestamp":1769063995,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YM1GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065170008.USD","BK4139","LU2065171311.SGD","FOLD","LU2065171402.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"2605433900","title":"Amicus Therapeutics Inc. Announces Date for Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2605433900","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605433900?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:19","pubTimestamp":1769030373,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics Inc. has announced that it will hold a special meeting of stockholders virtually via live webcast in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL3fl3J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065170008.USD","FOLD","LU2065169927.USD","BK4139","LU2065171311.SGD"],"gpt_icon":0},{"id":"2595725705","title":"It’s Earnings Warning Season. How to Profit From Others’ Misery","url":"https://stock-news.laohu8.com/highlight/detail?id=2595725705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595725705?lang=en_us&edition=fundamental","pubTime":"2026-01-01 23:00","pubTimestamp":1767279600,"startTime":"0","endTime":"0","summary":"January is an optimistic time of year for investors, but not necessarily for corporate America.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9c084b36ba0e1e4ad2a94bff2fcea0b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0109394709.USD","LULU","FOLD","BK4504","LU2362540622.SGD","LU0114720955.EUR","ALNY","LU1496350502.SGD","LU2237438978.USD","BK4139","LU0058720904.USD","SLAB","QDEL","LU2362541513.USD","DHR","LU0053666078.USD","LU0823416689.USD","BK4534","LU0889565916.HKD","LU2089984988.USD","BK4588","BK4200","BK4548","ANF","NVCR","EXAS","ILMN","IPAR","BK4121","IDCC","REGN","STAA","DXCM","BK4094","HALO","BK4535","CDNA","ORC","LU0823411888.USD","LU1917777945.USD","LU2362541273.HKD","LU2023250504.SGD","BK4202","LU0823434583.USD","TMUS","FIVE","LU1974910355.USD","LU0320765992.SGD","HOLX","LU2468319806.SGD","AEO","LU2106854487.HKD","LU0823434740.USD","PCRX","PTCT","BK4585","GMED","LU0882574055.USD"],"gpt_icon":0},{"id":"2595273373","title":"Amicus Therapeutics Cut to Market Perform From Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2595273373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595273373?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:04","pubTimestamp":1767017040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FOLD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 29, 2025 09:04 ET (14:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD"],"gpt_icon":0},{"id":"2595780917","title":"U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595780917?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:58","pubTimestamp":1767013115,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio Dec 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Expedia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nL4N3XZ0LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFMHRM44.USD","BK4585","LU0109394709.USD","LU1162221912.USD","LU0162691827.USD","FOLD","LU0889565916.HKD","PRAX","BK4201","LU0320765646.SGD","BK4142","BK4007","LU0320765992.SGD","LU0054578231.USD","LU1829250122.USD","LU2065169927.USD","BK4216","PALI","BP","LU2065170008.USD","BK4566","BK4190","LU2065171402.SGD","LU0072461881.USD","LU2065171311.SGD","BK4588","EXPE","BK4139","MTN","HAS"],"gpt_icon":0},{"id":"2595787658","title":"Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787658","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787658?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:10","pubTimestamp":1767010253,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (FOLD) has an average rating of overweight and mean price target of $14.83, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FOLD"],"gpt_icon":0},{"id":"2593443584","title":"Amicus Therapeutics Chief People Officer David Michael Clark Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593443584","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593443584?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:16","pubTimestamp":1766524605,"startTime":"0","endTime":"0","summary":"David Michael Clark, Chief People Officer of Amicus Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDLb9CSd2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Amicus Therapeutics Chief People Officer David Michael Clark Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","FOLD","LU2065169927.USD","BK4139","LU2065170008.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2593741765","title":"What's Going On With BioMarin Stock On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593741765","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593741765?lang=en_us&edition=fundamental","pubTime":"2025-12-24 02:05","pubTimestamp":1766513100,"startTime":"0","endTime":"0","summary":"BioMarin to acquire Amicus for $4.8 billion as analysts see $1 billion peak sales assets, EPS accretion, and stronger long-term rare disease growth.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/23/Biomarin.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/23/Biomarin.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/12/49568946/whats-going-on-with-biomarin-stock-on-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/25/12/49568946/whats-going-on-with-biomarin-stock-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["FOLD","IE00B7SZLL34.SGD","LU2065171402.SGD","IE00B19Z3581.USD","LU2065170008.USD","LU2065171311.SGD","IE0002270589.USD","LU2065169927.USD","BK4566","BK4139","IE00B19Z3B42.SGD","BMRN"],"gpt_icon":0},{"id":"2593438914","title":"Amicus Therapeutics Cut to Neutral From Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2593438914","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593438914?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:44","pubTimestamp":1766411040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FOLD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 08:44 ET (13:44 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD"],"gpt_icon":0},{"id":"2593482621","title":"TD Cowen Downgrades Amicus Therapeutics to Hold From Buy, Adjusts PT to $14.50 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2593482621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593482621?lang=en_us&edition=fundamental","pubTime":"2025-12-22 20:14","pubTimestamp":1766405687,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (FOLD) has an average rating of overweight and mean price target of $15.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FOLD","COWN","PT","TD"],"gpt_icon":0},{"id":"2593510240","title":"U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593510240?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:49","pubTimestamp":1766389793,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Comerica, Heico, WalmartDec 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comerica, Heico and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL4N3XS0F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","FRT","ANF","EOSE","IE00B19Z8X17.USD","CINF","AZZ","CRSR","ELF","FISV","FOLD","LU1951200564.SGD","AKTX","BMRN","APRE","LU2275660780.HKD","LU0689472784.USD","CWAN","LU0323591593.USD","COF","GOOGL","CFG","CYTK","BMBL","ASB","AFL","CUBE","CNTX","GAP","ALZN","LU0187121727.USD","LU2242649171.HKD","AXP","ALLY","FLUT","AIG","BOW","CMA","FITB","T","FBLG","CCL","HEI","LEU","BKSY","CAG","DRI","DKNG","BK4516","LU1116320737.USD"],"gpt_icon":1},{"id":"2593644105","title":"Amicus Therapeutics Inc : TD Cowen Cuts to Hold From Buy; Cuts Target Price to $14.5 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2593644105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593644105?lang=en_us&edition=fundamental","pubTime":"2025-12-22 12:48","pubTimestamp":1766378916,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS03I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065170008.USD","BK4139","LU2065169927.USD","LU2065171311.SGD","FOLD","LU2065171402.SGD"],"gpt_icon":0},{"id":"2593031731","title":"BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2593031731","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593031731?lang=en_us&edition=fundamental","pubTime":"2025-12-22 12:10","pubTimestamp":1766376612,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale** Shares of Dimerix DXB.AX rise as much as 12.5% to A$0.63, its highest level in seven months** Stock touches its biggest intraday pct gain in six months, if gains hold** Biotech co says U.S. listed biotech firm, BioMarin Pharmaceutical BMRN.O to acquire co's U.S. commercial licensing partner, Amicus Therapeutics for $4.8 billion** Amicus Therapeutics is a biopharma co, licensing DXB's drug, DMX-200, for U.S. market to treat rare kidney diseases** Stock up 80.89% YTD, including session's moves","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL6N3XS07Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK7067","DXB.AU","IE0002270589.USD","FOLD","IE00B19Z3B42.SGD","BK4139","IE00B7SZLL34.SGD","BMRN","BK7508","BK4566","LU2065170008.USD","LU2065171402.SGD","IE00B19Z3581.USD","LU2065169927.USD","BK7501"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amicusrx.com","stockEarnings":[{"period":"1week","weight":0.0014},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.5825},{"period":"6month","weight":1.2611},{"period":"1year","weight":0.4824},{"period":"ytd","weight":0.0035}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.06136},{"month":2,"riseRate":0.5,"avgChangeRate":-0.04086},{"month":3,"riseRate":0.555556,"avgChangeRate":0.039527},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.017744},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.009978},{"month":6,"riseRate":0.631579,"avgChangeRate":0.068706},{"month":7,"riseRate":0.578947,"avgChangeRate":0.084684},{"month":8,"riseRate":0.473684,"avgChangeRate":0.040961},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.011223},{"month":10,"riseRate":0.315789,"avgChangeRate":-0.067456},{"month":11,"riseRate":0.578947,"avgChangeRate":0.061605},{"month":12,"riseRate":0.526316,"avgChangeRate":-0.004164}],"exchange":"NASDAQ","name":"Amicus Therapeutics","nameEN":"Amicus Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amicus Therapeutics(FOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amicus Therapeutics,FOLD,Amicus Therapeutics股票,Amicus Therapeutics股票老虎,Amicus Therapeutics股票老虎国际,Amicus Therapeutics行情,Amicus Therapeutics股票行情,Amicus Therapeutics股价,Amicus Therapeutics股市,Amicus Therapeutics股票价格,Amicus Therapeutics股票交易,Amicus Therapeutics股票购买,Amicus Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amicus Therapeutics(FOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction